| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GUCY1A2 |
| Uniprot No | P33402 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 500-732aa |
| 氨基酸序列 | GDVAQQLWQGQQVQARKFDDVTMLFSDIVGFTAICAQCTPMQVISMLNELYTRFDHQCGFLDIYKVETIGDAYCVAAGLHRKSLCHAKPIALMALKMMELSEEVLTPDGRPIQMRIGIHSGSVLAGVVGVRMPRYCLFGNNVTLASKFESGSHPRRINVSPTTYQLLKREESFTFIPRSREELPDNFPKEIPGICYFLEVRTGPKPPKPSLSSSRIKKVSYNIGTMFLRETSL |
| 预测分子量 | 27.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GUCY1A2重组蛋白的参考文献示例(注：文献为假设性示例，实际检索需通过学术数据库验证)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant GUCY1A2 in Nitric Oxide Signaling*
**作者**：Zhang L, et al.
**摘要**：研究利用昆虫细胞系统表达重组GUCY1A2蛋白，证实其与β亚基形成异源二聚体，并在NO刺激下产生cGMP，揭示了其在血管舒张中的调控机制。
2. **文献名称**：*Crystallographic Characterization of Human GUCY1A2 Recombinant Protein*
**作者**：Thompson R, et al.
**摘要**：通过大肠杆菌表达并纯化GUCY1A2.结合X射线晶体学解析其三维结构，为靶向药物设计提供结构基础。
3. **文献名称**：*GUCY1A2 Genetic Variants and Recombinant Protein Activity in Pulmonary Hypertension*
**作者**：Martinez S, et al.
**摘要**：分析GUCY1A2基因突变对重组蛋白催化活性的影响，发现特定突变导致cGMP生成减少，与肺动脉高压发病相关。
4. **文献名称**：*High-Throughput Screening of GUCY1A2 Activators Using Recombinant Protein Assays*
**作者**：Kim H, et al.
**摘要**：开发基于重组GUCY1A2蛋白的体外筛选平台，鉴定出新型小分子激动剂，潜在用于心血管疾病治疗。
---
建议通过PubMed或Web of Science以关键词“GUCY1A2 recombinant”“sGC alpha2 subunit”检索最新文献，获取真实研究数据。
Gucylate cyclase 1A2 (GUCY1A2) is a subunit of the soluble guanylate cyclase (sGC) enzyme, which plays a critical role in the nitric oxide (NO)-mediated signaling pathway. As a heterodimer typically pairing with GUCY1B1 or GUCY1A1. it catalyzes the conversion of GTP to cyclic guanosine monophosphate (cGMP), a secondary messenger involved in vasodilation, platelet aggregation, and neuronal signaling. GUCY1A2 is expressed in various tissues, including vascular smooth muscle, the brain, and the gastrointestinal tract, highlighting its regulatory role in cardiovascular and neurological functions.
Recombinant GUCY1A2 protein is engineered using expression systems like *E. coli* or mammalian cells to produce functional, purified protein for research. Structural studies reveal its modular architecture, featuring a regulatory N-terminal domain, a catalytic domain, and a dimerization interface critical for sGC activity. Recombinant forms often include tags (e.g., His-tag) for affinity purification and may lack transmembrane domains to enhance solubility. This protein is pivotal in studying NO-sGC-cGMP pathway dysregulation linked to hypertension, atherosclerosis, and neurodegenerative disorders. Researchers utilize it to screen sGC-targeted therapeutics, such as NO-independent activators for treating resistant hypertension. Additionally, it aids in characterizing mutations affecting enzyme activity or ligand binding, offering insights into disease mechanisms. Its application extends to *in vitro* assays evaluating cGMP production kinetics and protein interaction studies to map signaling networks. Overall, recombinant GUCY1A2 serves as a vital tool for dissecting sGC biology and developing therapies for cardiovascular and neurological diseases.
×
